Equities Analysts Offer Predictions for HIMS Q3 Earnings

Key Points

• Investment analysts from Seaport Res Ptn predict Hims & Hers Health will earn $0.09 per share for Q3 2025, below the full-year consensus estimate of $0.29 per share.
• Hims & Hers Health reported $0.17 earnings per share for its last quarter, missing analysts' expectations of $0.18 and generating revenue of $544.83 million.
• The stock has seen mixed ratings, with three analysts recommending a sell, nine a hold, and two a buy, reflecting a cautious outlook among investors.

Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) - Investment analysts at Seaport Res Ptn issued their Q3 2025 EPS estimates for shares of Hims & Hers Health in a research report issued to clients and investors on Monday, August 4th. Seaport Res Ptn analyst A. Kessler forecasts that the company will earn $0.09 per share for the quarter. The consensus estimate for Hims & Hers Health's current full-year earnings is $0.29 per share. Seaport Res Ptn also issued estimates for Hims & Hers Health's Q4 2025 earnings at $0.11 EPS, FY2025 earnings at $0.56 EPS and FY2026 earnings at $0.78 EPS.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last posted its quarterly earnings results on Monday, August 4th. The company reported $0.17 earnings per share for the quarter, missing analysts' consensus estimates of $0.18 by ($0.01). Hims & Hers Health had a return on equity of 26.26% and a net margin of 9.63%. The company had revenue of $544.83 million for the quarter, compared to analyst estimates of $550.06 million. During the same period last year, the company earned $0.06 earnings per share. The business's revenue for the quarter was up 72.6% compared to the same quarter last year.

Several other equities research analysts have also commented on HIMS. Truist Financial boosted their price objective on shares of Hims & Hers Health from $45.00 to $48.00 and gave the stock a "hold" rating in a research report on Thursday, July 17th. Deutsche Bank Aktiengesellschaft reiterated a "hold" rating on shares of Hims & Hers Health in a research report on Wednesday, May 7th. UBS Group set a $30.00 price objective on shares of Hims & Hers Health in a research note on Monday, June 23rd. TD Cowen downgraded shares of Hims & Hers Health from a "buy" rating to a "hold" rating and dropped their price objective for the company from $44.00 to $30.00 in a research note on Tuesday, April 29th. Finally, Wall Street Zen downgraded shares of Hims & Hers Health from a "buy" rating to a "hold" rating in a research note on Monday, July 28th. Three investment analysts have rated the stock with a sell rating, nine have given a hold rating and two have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Hold" and an average target price of $39.83.

Hims & Hers Health Stock Performance

NYSE:HIMS opened at $51.30 on Thursday. The company has a quick ratio of 1.32, a current ratio of 4.98 and a debt-to-equity ratio of 1.72. Hims & Hers Health has a fifty-two week low of $13.47 and a fifty-two week high of $72.98. The stock has a market cap of $11.48 billion, a PE ratio of 64.12, a price-to-earnings-growth ratio of 2.06 and a beta of 2.08. The firm's fifty day simple moving average is $53.79 and its 200-day simple moving average is $44.63.

Institutional Trading of Hims & Hers Health

A number of institutional investors and hedge funds have recently modified their holdings of the company. Farallon Capital Management LLC grew its position in Hims & Hers Health by 64,338.5% in the fourth quarter. Farallon Capital Management LLC now owns 8,377,000 shares of the company's stock valued at $202,556,000 after acquiring an additional 8,364,000 shares during the period. Geode Capital Management LLC lifted its stake in Hims & Hers Health by 0.9% in the fourth quarter. Geode Capital Management LLC now owns 4,329,996 shares of the company's stock valued at $104,724,000 after buying an additional 40,447 shares during the period. Northern Trust Corp lifted its stake in Hims & Hers Health by 19.5% in the first quarter. Northern Trust Corp now owns 2,435,512 shares of the company's stock valued at $71,969,000 after buying an additional 397,310 shares during the period. Yong Rong HK Asset Management Ltd raised its position in shares of Hims & Hers Health by 41.2% during the first quarter. Yong Rong HK Asset Management Ltd now owns 2,400,000 shares of the company's stock worth $70,920,000 after purchasing an additional 700,100 shares during the period. Finally, Nuveen LLC acquired a new stake in shares of Hims & Hers Health during the first quarter worth about $58,403,000. 63.52% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, insider Soleil Boughton sold 2,572 shares of the business's stock in a transaction that occurred on Monday, July 28th. The stock was sold at an average price of $58.70, for a total transaction of $150,976.40. Following the sale, the insider directly owned 155,593 shares in the company, valued at approximately $9,133,309.10. The trade was a 1.63% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Andrew Dudum sold 125,335 shares of the business's stock in a transaction that occurred on Monday, July 21st. The shares were sold at an average price of $49.54, for a total value of $6,209,095.90. Following the sale, the chief executive officer owned 92,313 shares in the company, valued at approximately $4,573,186.02. This represents a 57.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 737,704 shares of company stock valued at $40,644,035 in the last quarter. Company insiders own 13.71% of the company's stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.